CD52 and peripheral T-cell lymphoma, not otherwise specified: Alemtuzumab, a monoclonal antibody targeting CD52, has been investigated as an adjunctive drug to the CHOP regimen in peripheral T-cell lymphoma [138,139,140]; however, only case reports of EATL patients treated with anti-CD52 have been reported, with conflicting results [141,142,143].